Draig Therapeutics secures $65M Series B to advance brain-drug trials

Draig Therapeutics announced a $65 million Series B financing led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace and other investors.

The capital will fund mid‑stage trials of the company’s experimental psychiatric medicines, including a candidate the firm says has best‑in‑disease potential for major depressive disorder.

Spun out of Cardiff University research and previously backed by a $140 million Series A, Draig is tackling the difficult brain‑disorder space with the aim of restoring chemical balance in patients’ brains.